Zygo enter into definitive merger agreement AMETEK.

We believe this purchase creates significant worth for Zygo stockholders and I am thrilled for the chance this deal represents for our customers and workers, said Gary Willis, Chief Executive Officer of Zygo. The closing of the transaction is at the mercy of customary closing conditions, like the authorization of Zygo's stockholders and applicable regulatory approvals. Kaufman, the Chairman of the Board of Zygo, which owns approximately 23 beneficially.6 percent of the outstanding shares of Zygo, in addition to Mr. Willis, have decided to vote their shares of Zygo common share in favor of the merger.. AMETEK, Zygo enter into definitive merger agreement AMETEK, Inc. and Zygo Corporation announced that they have entered right into a definitive merger contract under which AMETEK will acquire all of the outstanding shares of common stock of Zygo at a purchase price of $19.25 per share in cash, which represents a premium of 31 percent to Zygo'on April 10 s closing share price, 2014.The trial was overseen by an independent safety and data monitoring committee. ScvO2 monitors had been loaned to participating sites by Edwards Lifesciences, which acquired no other role in the carry out of the study. Study Population Patients 18 years or older who also met the eligibility requirements within 6 hours after presentation to the crisis department were assessed for enrollment. Eligibility criteria were a verified or suspected infection, two or more requirements for a systemic inflammatory response26 , and evidence of refractory hypotension or hypoperfusion. Refractory hypotension was defined as a systolic blood pressure of significantly less than 90 mm Hg or a indicate arterial pressure of significantly less than 65 mm Hg after an intravenous liquid challenge of 1000 ml or even more administered within a 60-minute period.